ClinicalTrials.gg
RecruitingNCT05858437Pro-KidsUpdated Nov 4, 2026

Impact of Propionic Acid on Regulatory T Cell Function in Children With CKD

An interventional study of Sodium propionate and Placebo in CKD (Chronic Kidney Disease) Stage 5D, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 12 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Nov 4, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
12 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 232 studies in Renal Insufficiency, Chronic with a site in Germany — 26 open to participants now, 43 under way, 19 of them phase 3. Renal Insufficiency, Chronic · Germany.

Planned enrollment
165th of 183
16 · median 140
Started
2024
with 12 others
No phase
31 of 232
5 open now
Primary completion
2026-07
later than 9 of 42 live
Registered
192nd of 232
by date
Lead sponsor
5 of 232
Charite University, Berlin, Germany

Among the 232 studies in Renal Insufficiency, Chronic with a site in Germany, this one is the 165th largest by planned enrollment of the 183 interventional ones that give a count, is one of 13 that started in 2024, is one of 31 with no phase, reaches primary completion later than 9 of the 42 other live ones, and was the 192nd registered.

Renal Insufficiency, Chronic

3,097 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

26 of the 232 studies in Renal Insufficiency, Chronic with a site in Germany are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 12 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Renal Insufficiency, Chronic with a site in Germany, or all of them as a file.
02

Study summary

Pro-Kids is a multi-center, double-blind, randomized and placebo-controlled intervention study in children with chronic kidney disease. The investigators address the effect of a dietary food supplementation of propionic acid on the immune system and the function of the intestinal barrier in CKD patients treated with hemodialysis.

Read the detailed description

Chronic inflammation is a major risk factor of cardiovascular disease progression in CKD, irrespective of confounding comorbidities. Based on current knowledge, microbially-derived metabolites such as short chain fatty acids (SCFA) play an important role in the regulation of chronic inflammatory processes in CKD patients. Children with CKD are known to have reduced serum levels of the SCFA propionic acid (PA), as a consequence of both gut microbial dysbiosis and reduced fiber intake. In animal and human studies the impact of PA on function and abundance of regulatory T cells (Treg) has been demonstrated. Consequently, the investigators aim to normalize the PA serum levels by oral PA food supplementation in hemodialysis patients in order to mitigate chronic inflammation.

03

Conditions studied

  • CKD (Chronic Kidney Disease) Stage 5D
04

Who can participate

Ages eligible
12 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight: > 30kg
  • CKD G5 treated with hemodialysis
  • Continuous hemodialysis treatment for > 3 months
  • Clinical stable condition
  • Manifestation of CKD within childhood (\<18 years)

Exclusion criteria

Exclusion Criteria:

  • Disease or dysfunctions, which disqualifies the patient
  • Incapacity of contract or any other circumstances, which prohibit the patient or his legal guardians from understanding setup, meaning and entity of the study
  • Acute infections
  • therapy within the last 12 weeks before the start of the study
  • Pre-/pro- or postbiotic or antibiotic therapy within the last 4 weeks before the start of the study
  • Planned or unplanned hospitalization within in last 4 weeks before the start of the study or during study
  • Malignant diseases
  • Pregnancy
  • chronic gastrointestinal or hepatic diseases (for example chronic inflammatory bowel disease
  • alcohol- or drug abuse
  • parallel participation on other interventional trials
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    PA Intervention

    The group which receives the PA as a dietary food supplement. A single capsule contains 500mg of sodiumpropionate, which is taken twice daily for 28 days.

    Dietary Supplement: Sodium propionate

  • Placebo comparator
    Placebo Intervention

    The control-group receives a placebo instead of propionate. The placebo contains maltodextrin and the same amount of sodium chloride as compared to the PA intervention. The placebo is taken twice per day for 28 days.

    Other: Placebo

Interventions

  • Dietary supplementSodium propionate

    The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.

  • OtherPlacebo

    The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.

06

What researchers measure

Primary outcomes

  1. Change in count of regulatory T-cells from baseline to week 4

    Analysis of Treg counts in whole blood (absolute quantification) and peripheral blood mononuclear cells (PBMC; relative quantification) by flow cytometry.

    Time frame: Baseline visit (week 0) in comparison to week 4

Secondary outcomes

  1. Propionic acid serum levels and targeted metabolomics

    Analysis of PA serum levels and other microbially-derived metabolites by GC-MS and LC-MS

    Time frame: Baseline visit (week 0); Week 2; Week 4; Week 12

  2. Immune cell phenotyping of peripheral blood mononuclear cells (PBMC)

    Patients PBMC will be thawed and immune cells we be analyzed using multicolor flow cytometry and mass cytometry. By using a broad range of different antibodies combined in several panels the investigators will analyse distinct T cell subtypes including markers of activation, but also other immune cells (including B cells, dendritic cells, monocytes, natural killer cells). Data will reported in relation to parent populations (e.g. T heller cells in % of T cells).

    Time frame: Baseline visit (week 0); Week 2; Week 4; Week 12

  3. T regulatory cell (Treg) suppression assay

    The suppressive capacity of patients Treg will be analyzed by co-cultivation with conventional, stimulated T cells (Tconv) in different proportions (Treg:Tconv). The proliferation of Tconv will be reported.

    Time frame: Baseline visit (week 0); Week 4

  4. Single cell RNA sequencing of immune cells

    Analysis of the transcriptome of immune cells using cellular indexing of transcriptomes and epitopes (CITEseq)

    Time frame: Baseline visit (week 0); Week 4

  5. Intestinal barrier function

    Analysis of biomarkers for intestinal barrier function, such as sCD14, zonulin-1 and LPS

    Time frame: Baseline visit (week 0); Week 2; Week 4; Week 12

  6. Taxonomy of the fecal microbiome

    The taxonomy of the fecal microbiome will be anayzed using 16S RNA amplicon sequencing.

    Time frame: Baseline visit (week 0); Week 4

  7. Cardiovascular Phenotyping

    Analysis of heart rate over time.

    Time frame: Baseline visit (week 0); Week 2; Week 4; Week 12

  8. Cardiovascular Phenotyping

    Analysis of blood pressure over time.

    Time frame: Baseline visit (week 0); Week 2; Week 4; Week 12

  9. Cholesterol levels

    Cholesterol levels will be assessed using standard clinical lab values.

    Time frame: Baseline visit (week 0); Week 2; Week 4; Week 12

07

Study locations

1 of 1 sites recruiting
  • Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin
    Berlin, State of Berlin 13353, Germany
    Recruiting
    • Johannes Holle, MD · Contact
    • Dominik Müller, MD · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Jul 2026, 29 months.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's 29 months is above that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Sep 2025 → Jul 2026 and completion Apr 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
May 15, 2023
StartActual
Jan 15, 2024
Primary completionActual
Jul 8, 2026was Sep 2025
CompletionEst.
Mar 2027was Apr 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin · Berlin, Germany
Show 1 removed
  • Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin · Berlin, Germany
Nov 4, 2026
Primary completion
Sep 2025→Jul 8, 2026 (actual)
Nov 4, 2026
Study completion
Apr 2026→Mar 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    1 site added, 1 site removed
    Show site
    • Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin · Berlin, Germany
    Show 1 removed
    • Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin · Berlin, Germany
    Primary completion Sep 2025→Jul 8, 2026 (now actual)
    Study completion Apr 2026→Mar 2027
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05858437
Responsible party
Johannes Benjamin Holle (Principal Investigator, Charite University, Berlin, Germany) — Principal investigator
First posted
May 15, 2023
Start date
Jan 15, 2024
Primary completion
Jul 8, 2026
Completion
Mar 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Johannes Holle, Dr. med.
Contact
johannes-benjamin.holle@charite.de
004930450516012
Nicola Wilck, Dr. med.
Contact
nicola.wilck@charite.de
004930450516012

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium propionate

Start the discussion